FRa Biology and FOLR1 IHC Scoring
Tuesday, March 14, from 12-1 p.m. CT
Exhibit hall room 2
Speaker: S. Michelle Shiller, D.O., PathGroup
Introducing the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic test that helps detect the Folate Receptor, α (FOLR1) biomarker in patients with epithelial ovarian cancer (EOC). By testing for FRα expression, labs can identify 35% of patients with EOC that may benefit from a promising FRα targeted therapy – ELAHERETM (mirvetuximab soravtansine). This comprehensive workshop aims to support pathologists with clinical training to better understand FRα biology and scoring of this novel IHC marker for EOC samples.